camostat has been researched along with Hypertension in 4 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We previously demonstrated that a high-salt (HS) diet provoked hypertension and proteinuria in Dahl salt-sensitive (DS) rats, accompanied by γENaC activation, which were attenuated by camostat mesilate (CM), an SP inhibitor." | 8.31 | A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats. ( Adachi, M; Deng, Q; Iwata, Y; Izumi, Y; Kakizoe, Y; Kuwabara, T; Miyasato, Y; Mukoyama, M; Nagayoshi, Y; Nakagawa, M; Nakagawa, T; Narita, Y; Nishiguchi, K, 2023) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 8.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Treatment with camostat mesilate or FOY-251 decreased equivalent current (Ieq) in M-1 cells in a dose-dependent manner and inhibited the protease activity of prostasin in vitro." | 5.35 | Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. ( Adachi, M; Kakizoe, Y; Kitamura, K; Ko, T; Maekawa, A; Miyoshi, T; Shiraishi, N; Tomita, K; Wakida, N, 2009) |
| " We previously demonstrated that a high-salt (HS) diet provoked hypertension and proteinuria in Dahl salt-sensitive (DS) rats, accompanied by γENaC activation, which were attenuated by camostat mesilate (CM), an SP inhibitor." | 4.31 | A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats. ( Adachi, M; Deng, Q; Iwata, Y; Izumi, Y; Kakizoe, Y; Kuwabara, T; Miyasato, Y; Mukoyama, M; Nagayoshi, Y; Nakagawa, M; Nakagawa, T; Narita, Y; Nishiguchi, K, 2023) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 4.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| "Treatment with camostat mesilate or FOY-251 decreased equivalent current (Ieq) in M-1 cells in a dose-dependent manner and inhibited the protease activity of prostasin in vitro." | 1.35 | Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. ( Adachi, M; Kakizoe, Y; Kitamura, K; Ko, T; Maekawa, A; Miyoshi, T; Shiraishi, N; Tomita, K; Wakida, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, Y | 2 |
| Deng, Q | 2 |
| Kakizoe, Y | 3 |
| Nakagawa, T | 2 |
| Miyasato, Y | 2 |
| Nakagawa, M | 1 |
| Nishiguchi, K | 1 |
| Nagayoshi, Y | 1 |
| Narita, Y | 1 |
| Izumi, Y | 2 |
| Kuwabara, T | 2 |
| Adachi, M | 3 |
| Mukoyama, M | 2 |
| Mizumoto, T | 1 |
| Uchimura, K | 1 |
| Hayata, M | 1 |
| Morinaga, J | 1 |
| Miyoshi, T | 2 |
| Sakai, Y | 1 |
| Tomita, K | 3 |
| Kitamura, K | 3 |
| Maekawa, A | 1 |
| Wakida, N | 1 |
| Ko, T | 1 |
| Shiraishi, N | 1 |
1 review available for camostat and Hypertension
| Article | Year |
|---|---|
Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.
Topics: Animals; Epithelial Sodium Channels; Esters; Furin; Gabexate; Guanidines; Humans; Hypertension; Rats | 2012 |
3 other studies available for camostat and Hypertension
| Article | Year |
|---|---|
A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats.
Topics: Animals; Blood Pressure; Fibrinolysin; Hypertension; Kidney; Podocytes; Proteinuria; Rats; Rats, Inb | 2023 |
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Esters; Guanidines; Hypertension; Male; | 2021 |
Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Esters; Gabexate; Gu | 2009 |